Dr. Travis Mickle President and CEO KemPharm describes the development of AZSTARYS, the stimulant-based methylphenidate prodrug treatment for ADHD one of the most common central nervous system diseases. This prodrug stimulates the norepinephrine dopamine reuptake inhibitor improving concentration, executive function, and irritability and provides for long-acting effect and protection from abuse as it is broken down in the lower GI. Travis' personal experience with ADHD and raising children with ADHD gives him a deep understanding of the challenges facing patients as well as their physicians.
@kempharm #Kempharm $KMPH #ADHD #CNS
KemPharm.com
Download the transcript here.
Empowered Patient Podcast